Althea share price on watch following online cannabis sales launch

The Althea share price is on watch this morning after the company announced it has launched online sales of medicinal cannabis.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Althea Group Holdings Ltd (ASX: AGH) share price is on watch this morning after the company announced it has launched online sales of medicinal cannabis. Patients can now order products online via the 'Althea Concierge' platform and have them delivered directly to their doors. This eliminates the need to visit a doctor or pharmacy in order to obtain the treatment on an ongoing basis.

cannabis leaves on a rising line graph representing growth of ASX cannabis share price

Image source: Getty Images

What does Althea do? 

Althea was founded in 2017 in Melbourne and holds licenses to import, cultivate, produce and supply medical cannabis.  The company has seen strong growth in customer numbers since launching. By the end of March this year, Althea had supplied medical cannabis to over 5,000 Australian patients. The company also has a manufacturing facility in Canada, Peak Processing Solutions. This facility produces 'Legalisation 2.0' products such as edibles, beverages, and cosmetic applications. 

How do online cannabis sales work?

The Althea Concierge platform, which is a TGA registered medical device, has been comprehensively updated to facilitate online sales and interactive, customisable treatment plans. Used in conjunction with telemedicine, the platform allows doctors to prescribe Althea medical cannabis products. Patients pay for their prescriptions online and medication is then delivered directly to their doors. This then eliminates the ongoing need for multiple visits to doctors and pharmacies . 

The new interactive treatment plan feature allows doctors to issue personalised treatment plans directly to patients' phones. This provides patients with customised dosage reminders and allows them to record their usage and provide ongoing feedback to their doctors. Anonymous patient symptom data will contribute to a body of evidence in support of Althea medications. 

Althea CEO, Josh Fegan said, "We are very excited about this latest update to the Althea Concierge platform. The ability for contactless sales is probably the biggest development yet for medicinal cannabis in Australia". Althea plans to roll out the updated version of its Concierge platform in the United Kingdom, where the company launched in June 2019, in the coming months. 

What is the outlook for the Althea share price?

Althea has been expanding rapidly since its inception. It has gained significant numbers of Australian patients and prescribers as well as launched in the UK. The company has also commenced manufacture in Canada and begun supplying products to Germany. It certainly appears as if Althea is set to make its mark on the medicinal cannabis industry. In the first half of FY20, the company reported a 963.8% increase in revenues. Investors are eagerly awaiting full year results to see if Althea can continue its trajectory.  

Motley Fool contributor Kate O'Brien has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A boy bounds after a big colourful bouncing ball in a grassy field.
Share Market News

ASX 200 energy shares lead and market finally cracks 8-day losing streak

The ASX 200's painful 8-day slide finally ended on Friday.

Read more »

Business people discussing project on digital tablet.
Broker Notes

Buy, hold, sell: Mesoblast, Mineral Resources, and Woolworths shares

Analysts have given their verdict on these shares. Let's see what they are saying.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Broker Notes

These top ASX 200 shares could rise 30% to 40%

Analysts are predicting big things from these shares. Let's find out why.

Read more »

Stacks of coins in a row with each higher than the last, and a person standing on top of each one watching them grow.
Dividend Investing

How I'd invest $2,000 in high-yield ASX 300 shares

I rate these businesses as strong buys for the long-term.

Read more »

A rueful woman tucks into a sweet pie as she contemplates a decision with regret.
Share Fallers

The worst 4 ASX 200 stocks to buy and hold in April unmasked

Investors sent these four ASX 200 stocks tumbling 21% to 44% in April.

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Share Fallers

Why these top ASX shares sank 10%+ in April

It was a tough month for these popular shares.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Broker Notes

Buy, hold, sell: Netwealth, PLS, and Reliance shares

Morgans has given its verdict on these shares. Let's see what the broker is saying.

Read more »